Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Caron A Jacobson ,Patrick M Reagan,Clare Spooner,Armin Ghobadi,Frederick L Locke,Kanwarjit Singh,Yi Lin,David B Miklos,Javier Muñoz,Rhine R Shen,Jinghui Dong,Roshan Karalliyadda,Adrian Bot,Abhinav Deol,John M Timmerman,Umar Farooq,Tanya Siddiqi,Sattva S Neelapu,Lazaros J Lekakis,Olalekan O Oluwole,Ian W Flinn,Brian T Hill,André Goy ,Jaeyeon Kim ,Patrick J Stiff ,Yunxiang Zheng

doi:10.1182/blood-2021-148078

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Caron A Jacobson , Patrick M Reagan + Show 24 more

Open Access

https://doi.org/10.1182/blood-2021-148078

Copy DOI

#Equity Holder In Publicly-traded Company #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Full Text